Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

  • Eva Domingo-Domènech
  • , Barbara Pro
  • , Tim Illidge
  • , Steven Horwitz
  • , Lorenz Trumper
  • , Swami Iyer
  • , Ranjana Advani
  • , Nancy L. Bartlett
  • , Jacob Haaber Christensen
  • , Won Seog Kim
  • , Tatyana Feldman
  • , Ilseung Choi
  • , Giuseppe Gritti
  • , David Belada
  • , Andrei Shustov
  • , Arpad Illes
  • , Pier Luigi Zinzani
  • , Andreas Hüttmann
  • , Marek Trneny
  • , Steven Le Gouill
  • Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage

Research output: Contribution to journalLetterpeer-review

Abstract

Trial registration: ClinicalTrials.gov

Original languageEnglish
Article number129
JournalBlood cancer journal
Volume15
Issue number1
DOIs
StatePublished - Dec 2025

Fingerprint

Dive into the research topics of 'Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up'. Together they form a unique fingerprint.

Cite this